Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8149332 | 0.81 | MAPT (0.36) | HSD17B10ALDH1A1LMNACYP1A2CYP2C19 | |
| SCHEMBL10044416 | 0.80 | PTGS2 (0.43) | HSD17B10ALDH1A1LMNACYP1A2CYP2C19 | |
| SCHEMBL10044414 | 0.79 | HSD17B10 (0.39) | HSD17B10ALDH1A1LMNACYP1A2CYP2C19 | |
| SCHEMBL7803958 | 0.78 | HSD17B10 (0.45) | HSD17B10ALDH1A1LMNACYP1A2NR1H3 | |
| SCHEMBL18770684 | 0.74 | KAT2B (0.42) | HSD17B10ALDH1A1PTGS2 | |
| SCHEMBL8859418 | 0.74 | HSD17B10 (0.44) | HSD17B10ALDH1A1LMNACYP1A2CYP2C19 | |
| SCHEMBL11248494 | 0.72 | LMNA (0.43) | HSD17B10ALDH1A1LMNA | |
| SCHEMBL23403285 | 0.70 | KDM4E (0.45) | ALDH1A1LMNAESR1NR1H3 | |
| SCHEMBL11393727 | 0.70 | HSD17B10 (0.50) | HSD17B10ALDH1A1USP2 | |
| SCHEMBL936893 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1441732-A2 | THIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003039451-A2 | THIAZOLE PYRIDAZINONES AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | MC2R, CYP2C9, OXTR | HSD17B10 391/4885ALDH1A1 630/4885LMNA 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.